BUSINESS

Follow-On AGs Gaining Ground with 10 Launches in 2 Years, More Expected amid Generic Quality Concerns

September 9, 2021

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Japan has seen a growing number of authorized generics (AGs) being launched as latecomers following conventional copycat drugs on the market. At least seven APIs of these “follow-on AGs” were listed in FY2020, and five more are expected in FY2021.…

To read the full story

Teva Takeda Set to Roll Out 2nd Blopress AG but Denies Competition with ASKA
August 17, 2021
Viatris Rolls Out 3 Follow-On AGs for Norvasc, Cardenalin, Relpax
March 8, 2021
“Follow-On” Authorized Generics Gaining Ground in Matured Gx Markets; TS-1 Grabs 80% Share
September 4, 2018

BUSINESS

Takeda Says US Revamp “Not Simply Workforce Reduction” as 634 Roles Impacted
April 3, 2026
New JCR President Confident in 100 Billion Yen Sales Target in 2030s
April 3, 2026
Meiji Launches Rezurock in Thailand
April 3, 2026
Mochida, LG Chem Ink Licensing Deal for Dienogest in South Korea, Thailand
April 3, 2026
Lotte Invests in Rakuten Medical via Biopharma CVC
April 3, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Japan’s FY2026 R&D Tax Credit Reform Wins Broad Industry Backing

By Sakura Kono

Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…

COLUMN

Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing

By Philip Carrigan

Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…